Device Trial Radar · NCT07931534
Pediatric Adeno-Tonsillar Hypertrophy Treatment Post-Approval Study
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
73
Planned (sponsor's estimate)
Start
Nov 5, 2026
Primary completion
May 6, 2028
Study completion May 6, 2028
Sponsor
- Lead sponsor
- ENTire Medical Ltd.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Nov 12, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 3 years, up to 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a prospective, multi-center, single-arm study of pediatric subjects (age 3-12) with Sleep-Disordered Breathing ("SDB") due to adeno-tonsillar hypertrophy which are treated with the ENTire IRE System. Subjects will be followed for six (6) months post-treatment. The objective of the study is to provide an ongoing safety and effectiveness assessment of the ENTire IRE System in treating pediatric adeno-tonsillar hypertrophy.
Conditions
- Airway Obstruction Upper
- Tonsillectomy
- Adenoidectomy Surgery
- Hypertrophy
Interventions
Irreversible ElectroporationDevice
The bi-polar IRE System locally applies short, high-voltage (HV) pulses, increasing the permeability of tissue cells, creating non-thermal irreversible electroporation (NTIRE). The energy is transferred via bipolar forceps handpiece causing irreversible cell membrane perforation and apoptosis resulting in tissue reduction. The clinical effect is anticipated within 2 to 4 weeks post-treatment.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Device- or Procedure-Related Adverse Events (Bleeding, Readmission, Dehydration, or Emergency Department Visit)Time frame: 6 months
- Time From Treatment to First Wong-Baker FACES Pain Scale Score of 2 or BelowTime frame: From procedure until the end of the first week post procedure (7 days)
- Change From Baseline in OSA-18 Total Score at 3 MonthsTime frame: 3 months post treatment
1 more outcomes with a free account
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Children's Hospital Colorado
Denver, Colorado
UT Southwestern Medical Center
Dallas, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.